Progression of liver fibrosis in HCV-positive liver transplant recipients randomized to everolimus with reduced calcineurin inhibitor (CNI) therapy or a standard CNI regimen

被引：6
|
作者：
Saliba, Faouzi [1 ]
Nevens, Frederik [2 ]
机构：
[1] Univ Paris 11, Hop Paul Brousse, Villejuif, France
[2] Katholieke Univ Leuven, Univ Hosp Gasthuisberg, Leuven, Belgium
来源：
TRANSPLANT INTERNATIONAL | 2015年 / 28卷 / 03期
关键词：
RENAL-FUNCTION;
D O I：
10.1111/tri.12449
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：373 / 374
页数：2
相关论文
共 50 条
  • [1] The effect of calcineurin inhibitor usage on hepatic fibrosis progression in HCV-positive liver transplant recipients: A two-centre study.
    van der Laan, L. J. W.
    Thomas, R. C.
    Zondervan, P. E.
    Lindsay, A. S.
    Burt, A. D.
    Hudson, M.
    Kazemier, G.
    Tilanus, H. W.
    Bassendine, M. F.
    Metselaar, H. J.
    [J]. LIVER TRANSPLANTATION, 2007, 13 (06) : S152 - S152
  • [2] Ab initio Everolimus-Based vs. Standard CNI Immunosuppression-Regimen in Liver Transplant Recipients
    Manzia, Tommaso Maria
    Quaranta, Claudia
    Toti, Luca
    Sforza, Daniele
    Pellicciaro, Marco
    Vella, Ivan
    Tariciotti, Laura
    Tisone, Giuseppe
    [J]. TRANSPLANTATION, 2018, 102 : S384 - S384
  • [3] Calcineurin inhibitor (CNI) withdrawal in adult liver transplant recipients: An analysis of long term efficacy
    Thompson, Julie A.
    Radosevich, David M.
    Humar, Abhi
    Lake, John R.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 : 544 - 544
  • [4] CALCINEURIN INHIBITOR (CNI) WITHDRAWAL IN ADULT LIVER TRANSPLANT RECIPIENTS: AN ANALYSIS OF LONG TERM EFFICACY.
    Thompson, Julie A.
    Radosevich, David M.
    Humar, Abhi
    Lake, John R.
    [J]. LIVER TRANSPLANTATION, 2008, 14 (07) : S107 - S107
  • [5] A Randomized Trial of Everolimus Initiation and Calcineurin Inhibitor (CNI) Elimination in Stable Heart Transplant Recipients With Impaired Renal Function
    Derthoo, D.
    Van Caenegem, O.
    De Pauw, M.
    Nellessen, E.
    Duerinckx, N.
    Ciarka, A.
    Droogne, W.
    Van Cleemput, J.
    Belmans, A.
    Meyns, B.
    Vanhaecke, J.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2014, 33 (04): : S14 - S14
  • [6] Everolimus with early withdrawal or reduced dose Calcineurin-Inhibitors (CNI) improves renal function in Liver Transplant (LT) Recipients: A Meta analysis
    Sahebjam, Frahad
    Mittal, Sahil
    Sood, Gagan K.
    [J]. HEPATOLOGY, 2014, 60 : 459A - 459A
  • [7] Ab initio Everolimus-based Versus Standard Calcineurin Inhibitor Immunosuppression Regimen in Liver Transplant Recipients
    Manzia, T. M.
    Angelico, R.
    Toti, L.
    Grimaldi, C.
    Sforza, D.
    Vella, I.
    Tariciotti, L.
    Lenci, I.
    Breshanaj, G.
    Baiocchi, L.
    Tisone, G.
    [J]. TRANSPLANTATION PROCEEDINGS, 2018, 50 (01) : 175 - 183
  • [8] Immunosuppression in HCV-positive liver-transplant recipients
    Chan, Aaron James
    Lake, John R.
    [J]. CURRENT OPINION IN ORGAN TRANSPLANTATION, 2012, 17 (06) : 648 - 654
  • [9] Safety of reconversion to calcineurin inhibitor (CNI) based immunosuppression in liver transplant recipients who had been converted to everolimus for post-transplant renal impairment
    Dayangac, M.
    [J]. TRANSPLANTATION, 2018, 102 : 213 - 213
  • [10] A trial of immunosuppressive agents in HCV-positive liver transplant recipients
    [J]. Nature Clinical Practice Gastroenterology & Hepatology, 2008, 5 (2): : 64 - 64
12345